〔1〕GAJEWSKA M, GORYŃSKI P, PARADOWSKASTANKIEWICZ
I, et al. Monitoring of Community-
Acquired Pneumonia Hospitalisations before the
Introduction of Pneumococcal Conjugate Vaccine into
Polish National Immunisation Programme (2009-2016):
A Nationwide Retrospective Database Analysis〔J〕.
Vaccine, 2020, 38(2): 194-201.
〔2〕SAVVATEEVA E N, RUBINA A Y, GRYADUNOV D A.
Biomarkers of Community-Acquired Pneumonia: A Key
to Disease Diagnosis and Management〔J〕. Biomed
Res Int, 2019, 2019: 1701276.
〔3〕DIVINO V, SCHRANZ J, EARLY M, et al. The Annual
Economic Burden among Patients Hospitalized
for Community-Acquired Pneumonia (CAP): A
Retrospective US Cohort Study〔J〕. Curr Med Res
Opin, 2020, 36(1): 151-160.
〔4〕瞿介明, 曹彬. 中国成人社区获得性肺炎诊断和治疗
指南(2016 年版)〔J〕. 中华结核和呼吸杂志, 2016,
39(4): 253-279.
〔5〕HAVELKA A, SEJERSEN K, VENGE P, et al. Calprotect
in, a New Biomarker for Diagnosis of Acute Respiratory
Infections〔J〕. Sci Rep, 2020, 10(1): 4208.
〔6〕DE GROOT R C A, MEYER SAUTEUR P M, UNGER
W W J, et al. Things That Could Be Mycoplasma
pneumoniae〔J〕. J Infect, 2017, 74(Suppl 1):
S95-S100.
〔7〕LIAPIKOU A, CILLONIZ C, PALOMEQUE A, et al.
Emerging Antibiotics for Community-Acquired
Pneumonia〔J〕. Expert Opin Emerg Drugs, 2019,
24(4): 221-231.
〔8〕HASAN M J, RABBANI R. Extensive Pneumocephalus
Caused by Multidrug-Resistant Klebsiella Pneumoniae〔J〕.
World Neurosurg, 2020, 137: 29-30.
〔9〕KAMAT I S, RAMACHANDRAN V, ESWARAN H,
et al. Procalcitonin to Distinguish Viral from Bacterial
Pneumonia: A Systematic Review and Meta-Analysis〔J〕.
Clin Infect Dis, 2020, 70(3): 538-542.
〔10〕GUO S, MAO X, LIANG M. The Moderate Predictive
Value of Serial Serum CRP and PCT Levels for the
Prognosis of Hospitalized Community-Acquired
Pneumonia〔J〕. Respir Res, 2018, 19(1): 193.
〔11〕朱宇敏. 中性粒细胞- 淋巴细胞比值和C- 反应蛋白
在细菌性社区获得性肺炎诊断中的临床价值〔J〕.
临床与病理杂志, 2017, 37(6): 1220-1225.
〔12〕RAMIREZ J A, WIEMKEN T L, PEYRANI P, et al.
Adults Hospitalized with Pneumonia in the United
States: Incidence, Epidemiology, and Mortality〔J〕.
Clin Infect Dis, 2017, 65(11): 1806-1812.
〔13〕KOLDITZ M, TESCH F, MOCKE L, et al. Burden
and Risk Factors of Ambulatory or Hospitalized CAP:
A Population Based Cohort Study〔J〕. Respir Med,
2016, 121: 32-38.
〔14〕ZHYDKOV A, CHRIST-CRAIN M, THOMANN
R, et al. Utility of Procalcitonin, C-Reactive Protein
and White Blood Cells Alone and in Combination for
the Prediction of Clinical Outcomes in Community-
Acquired Pneumonia〔J〕. Clin Chem Lab Med, 2015,
53(4): 559-566.
〔15〕ZHENG W F, ZHAN J Q, CHEN A H, et al. Diagnostic
Value of Neutrophil-Lymphocyte Ratio in
Preeclampsia: A PRISMA-Compliant Systematic
Review and Meta-Analysis〔J〕. Medicine, 2019,
98(51): e18496.
〔16〕CURBELO J, RAJAS O, ARNALICH B, et al. Neutrophil
Count Percentage and Neutrophil-Lymphocyte
Ratio as Prognostic Markers in Patients Hospitalized
for Community-Acquired Pneumonia〔J〕. Arch
Bronconeumol (Engl Ed), 2019, 55(9): 472-477.
〔17〕NEESER O L, VUKAJLOVIC T, FELDER L, et al. A
High C-Reactive Protein/Procalcitonin Ratio Predicts
Mycoplasma pneumoniae Infection〔J〕. Clin Chem
Lab Med, 2019, 57(10): 1638-1646.
|